文献速递浆细胞疾病

伊沙佐米/来那度胺/地塞米松治疗复发/难治多发性骨髓瘤:中国多中心真实世界研究

[The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2021-01-01

国内14个中心纳入74例复发/难治多发性骨髓瘤患者,接受IRd方案治疗。总体反应率54.1%,中位无进展生存9.9个月,中位总生存20个月,3~4级不良事件发生率36.5%。

要点

  • IRd方案在中国复发/难治MM患者中ORR为54.1%,中位PFS 9.9个月。
  • 硼替佐米和来那度胺双药难治患者ORR为33.3%。
  • 3~4级不良事件发生率36.5%,主要为血液学毒性。

核心结论

  • IRd方案治疗中国复发/难治MM具有较好的疗效及可接受的毒性。

研究设计与样本

  • 国内14个中心纳入2018年7月至2020年5月接受至少1个周期IRd方案的复发/难治MM患者74例。
  • 伊沙佐米起始口服剂量4 mg,7例首次给药时调整至3 mg;来那度胺剂量根据肌酐清除率调整。

主要发现

  • 总体反应率54.1%(40/74),其中严格意义的完全缓解或完全缓解7例(9.5%),非常好的部分缓解14例(18.9%),部分缓解19例(25.7%)。
  • 中位无进展生存时间9.9个月,中位总生存时间20个月,中位获得反应时间1个月。
  • 硼替佐米难治、来那度胺难治、两药均难治患者ORR分别为52.0%(13/25)、57.1%(4/7)和33.3%(6/18)。
  • 3~4级不良事件发生率36.5%(27/74),2例出现3级周围神经病变。
  • 符合TOURMALINE-MM1中国延展性研究入组标准者ORR更高[77.8%(14/18)对46.4%(26/56),P=0.020],3~4级AE发生率无差异[33.3%(6/18)对37.5%(21/56),P=0.749]。

关键数值与推荐

  • 总体反应率54.1%(40/74)。
  • 中位无进展生存9.9个月,中位总生存20个月。
  • 3~4级不良事件发生率36.5%(27/74)。
  • 符合TOURMALINE-MM1 CCS入组标准者ORR 77.8%(14/18)对46.4%(26/56),P=0.020。

临床怎么用

  • IRd可作为中国复发/难治MM患者的治疗选择之一。
  • 来那度胺剂量需根据肌酐清除率调整。
  • 治疗中需关注血液学毒性及周围神经病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety profile of ixazomib/lenalidomide/dexamethasone (IRd) in Chinese patients with relapsed/refractory multiple myeloma (MM) . Methods: This study comprising 14 medical centers in China included patients with relapsed/refractory MM who received at least. Ixazomib at an initial oral dose of 4 mg was administered. Seven patients had dose adjustment to 3 mg at the time of first dose. The lenalidomide doses were adjusted according to creatinine clearance rate. The efficacy and safety were evaluated every cycle. Results: In the study cohort of 74 patients, the median age was 65 years and 11 (14.9% ) patients received over three lines of therapy. Overall response rate (ORR) was 54.1% (40/74) , and 7 (9.5% ) , 14 (18.9% ) , and 19 (25.7% ) patients achieved stringent complete response or complete response, very good partial response, and partial response, respectively. The median progression-free survival and overall survival were 9.9 and 20 months, respectively. The median time to response was 1 month. The efficacy and survival outcome were similar to those reported in the Tourmaline-MM1 China Continuous Study. The ORR of patients refractory to bortezomib, lenalidomide, and bortezomib plus lenalidomide were 52.0% (13/25) , 57.1% (4/7) , and 33.3% (6/18) , respectively. The rate of grade 3-4 adverse events was 36.5% (27/74) . Common hematological toxicities were anemia, thrombocytopenia, lymphopenia, and neutropenia. Common non-hematological toxicities were fatigue, gastrointestinal symptoms, and infections. Two cases of grade 3 peripheral neuropathy were reported. The patients eligible for the Tourmaline-MM1 China Continuous Study had a higher ORR than the ineligible patients [77.8% (14/18) vs 46.4% (26/56) , P=0.020]. There was no difference in the rate of grade 3-4 adverse events [33.3% (6/18) vs 37.5% (21/56) , P=0.749]. Conclusion: The IRd regimen had good efficacy and acceptable toxicity in Chinese patients with relapsed/refractory MM. 目的: 评估伊沙佐米、来那度胺、地塞米松(IRd)方案治疗复发/难治多发性骨髓瘤(MM)的疗效及安全性。 方法: 纳入2018年7月至2020年5月于国内14个中心接受至少1个周期IRd方案治疗的复发/难治MM患者。除7例起始剂量作调整的患者以外,其余患者伊沙佐米起始剂量为4 mg。来那度胺剂量根据患者肌酐清除率进行调整。每周期进行疗效及安全性评估。 结果: 共纳入74例患者,中位年龄65岁,11例(14.9%)患者曾接受>三线治疗。总体反应率(ORR)为54.1%(40/74),其中7例(9.5%)达严格意义的完全缓解或完全缓解,14例(18.9%)达非常好的部分缓解,19例(25.7%)达部分缓解,中位无进展生存时间为9.9月,中位总生存时间为20个月,中位获得反应时间为1个月。总体疗效与生存结果与TOURMALINE-MM1中国延展性研究(TOURMALINE-MM1 CCS)相近。硼替佐米难治、来那度胺难治、两药均难治患者的ORR分别为52.0%(13/25)、57.1%(4/7)和33.3%(6/18)。3~4级不良事件(AE)发生率为36.5%(27/74)。主要血液学不良反应为贫血、血小板减少、淋巴细胞减少及中性粒细胞减少。主要非血液学不良反应为乏力、消化道症状及感染。2例患者出现3级周围神经病变。与不符合TOURMALINE-MM1 CCS试验入组标准的患者相比,符合入组标准的患者ORR更高[77.8%(14/18)对46.4%(26/56),P=0.020],两组3~4级AE发生率的差异无统计学意义[33.3%(6/18)对37.5%(21/56),P=0.749]。 结论: IRd方案治疗复发/难治MM具有较好的疗效及安全性。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang Y, Xia ZJ, Zhang WH, et al. [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34547867. doi:10.3760/cma.j.issn.0253-2727.2021.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。